Literature DB >> 19201002

Grey matter pathology in clinically early multiple sclerosis: evidence from magnetic resonance imaging.

Declan Chard1, David Miller.   

Abstract

In multiple sclerosis (MS) it is emerging that the most visible element of pathology, white matter (WM) lesions, represents only a fraction of the disease burden borne by the brain; non-lesional WM is also damaged, as is the grey matter (GM). Evidence is also accruing that GM damage may be a major determinant of longer-term outcomes in MS, and that such damage occurs from the earliest clinical stages of the disease. In this review, we focus on the early stages of relapse onset MS, considering the nature, extent and evolution of GM pathology, as determined using magnetic resonance imaging.

Entities:  

Mesh:

Year:  2009        PMID: 19201002     DOI: 10.1016/j.jns.2009.01.012

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  37 in total

1.  In vivo evidence of disseminated subpial T2* signal changes in multiple sclerosis at 7 T: a surface-based analysis.

Authors:  J Cohen-Adad; T Benner; D Greve; R P Kinkel; A Radding; B Fischl; B R Rosen; C Mainero
Journal:  Neuroimage       Date:  2011-04-13       Impact factor: 6.556

2.  Gray matter pathology in MS: a 3-year longitudinal study in a pediatric population.

Authors:  M Calabrese; D Seppi; C Romualdi; F Rinaldi; S Alessio; P Perini; P Gallo
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-15       Impact factor: 3.825

3.  (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas.

Authors:  Eunkyung Park; Jean-Dominique Gallezot; Aracely Delgadillo; Shuang Liu; Beata Planeta; Shu-Fei Lin; Kevin C O'Connor; Keunpoong Lim; Jae-Yun Lee; Anne Chastre; Ming-Kai Chen; Nicholas Seneca; David Leppert; Yiyun Huang; Richard E Carson; Daniel Pelletier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-02       Impact factor: 9.236

Review 4.  Defining Disease Activity and Response to Therapy in MS.

Authors:  Ulrike W Kaunzner; Mais Al-Kawaz; Susan A Gauthier
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

Review 5.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

6.  Can we overcome the 'clinico-radiological paradox' in multiple sclerosis?

Authors:  Kerstin Hackmack; Martin Weygandt; Jens Wuerfel; Caspar F Pfueller; Judith Bellmann-Strobl; Friedemann Paul; John-Dylan Haynes
Journal:  J Neurol       Date:  2012-03-24       Impact factor: 4.849

7.  Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL.

Authors:  Roland Opfer; Ann-Christin Ostwaldt; Christine Walker-Egger; Praveena Manogaran; Maria Pia Sormani; Nicola De Stefano; Sven Schippling
Journal:  J Neurol       Date:  2018-03-16       Impact factor: 4.849

8.  Changes and variability of proton density and T1 relaxation times in early multiple sclerosis: MRI markers of neuronal damage in the cerebral cortex.

Authors:  René-Maxime Gracien; Sarah C Reitz; Stephanie Michelle Hof; Vinzenz Fleischer; Hilga Zimmermann; Amgad Droby; Helmuth Steinmetz; Frauke Zipp; Ralf Deichmann; Johannes C Klein
Journal:  Eur Radiol       Date:  2015-10-22       Impact factor: 5.315

9.  Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosis.

Authors:  Nikos Gorgoraptis; Claudia A M Wheeler-Kingshott; Thomas M Jenkins; Daniel R Altmann; David H Miller; Alan J Thompson; Olga Ciccarelli
Journal:  Mult Scler       Date:  2010-03-09       Impact factor: 6.312

Review 10.  Is multiple sclerosis a mitochondrial disease?

Authors:  Peizhong Mao; P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2009-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.